Amgen and Sandoz face off again over biosimilars

Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel (etanercept).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen sues generic drug maker over bone treatments

4 May 2023 Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

Big Pharma

Amgen faces struggle to revive cholesterol patents, says Fed Circ judge

14 December 2020 Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.

Americas

Sandoz to appeal against Amgen biosimilar ruling

13 August 2019 Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.

More on this story

Americas

Amgen sues generic drug maker over bone treatments

4 May 2023 Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

Big Pharma

Amgen faces struggle to revive cholesterol patents, says Fed Circ judge

Americas

Sandoz to appeal against Amgen biosimilar ruling

More on this story

Americas

Amgen sues generic drug maker over bone treatments

4 May 2023 Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

Big Pharma

Amgen faces struggle to revive cholesterol patents, says Fed Circ judge

Americas

Sandoz to appeal against Amgen biosimilar ruling